Clinicopathological study and Management of Thyroid Malignancies by Sridev, M B
CLINICOPATHOLOGICAL STUDY AND  
MANAGEMENT OF THYROID  MALIGNANCIES 
 
 
 
 
 
 
 
 
 
 
By 
DR M B SRIDEV.,MBBS., 
Dissertation Submitted to the 
 
TAMIL NADU DR MGR MEDICAL UNIVERSITY 
In partial fulfillment 
of the requirements for the degree of 
MASTER OF SURGERY 
in 
GENERAL SURGERY 
Under the guidance of 
PROF P RAGUMANI.,M S., PROFESSOR 
DEPARTMENT OF GENERAL SURGERY 
MMC & RGGGH 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
DEPARTMENT OF GENERAL SURGERY 
MADRAS MEDICAL COLLEGE AND RGGGH 
CHENNAI—600003 
 
APRIL - 2013 
 
  i
 
DECLARATION BY THE CANDIDATE 
 
 I hereby declare that this dissertation 
“CLINICOPATHOLOGICAL STUDY AND MANAGEMENT OF 
THYROID MALIGNANCIES” is a bonafide and genuine research 
work carried out by me under the guidance of PROF P RAGUMANI., 
M.S., Professor, Department of General Surgery, MMC& RGGGH, 
CHENNAI. 
 
 
 
 
DATE: 
PLACE:                                                         DR M B SRIDEV 
                                                       PG IN GENERAL SURGERY 
                                                   MMC & RGGGH 
 
 
 
 
  ii
 
 
CERTIFICATE BY THE GUIDE 
 
 
This is to certify that the dissertation entitled 
“CLINICOPATHOLOGICAL 
STUDY AND MANAGEMENT OF THYROID MALIGNANCIES” 
is a bonafide 
research work done by Dr. M B SRIDEV in partial fulfillment of the 
requirement for the degree of Master of Surgery in General Surgery. 
 
 
 
DATE 
PLACE                                  PROF P RAGUMANI.,MS., 
 PROFESSOR 
                        DEPT OF GENERAL SURGERY 
                                      MMC & RGGGH 
 
 
  iii
 
ENDORSEMENT BY THE HEAD OF THE 
DEPARTMENT AND DEAN 
 
                         This is to certify that the dissertation entitled 
“CLINICOPATHOLOGICAL STUDY AND MANAGEMENT OF 
THYROID MALIGNANCIES” 
is a  bonafide  research work done by Dr. M B SRIDEV under the 
guidance  of  PROF P RAGUMANI.,MS., Professor, Department of 
General Surgery , MMC & RGGGH, CHENNAI. 
 
 
Prof. S. DEIVANAYAGAM  
HOD, Dept. of General Surgery   
MMC & RGGGH, Chennai  
Prof. V. KANGASABAI  
THE DEAN 
MMC & RGGGH,  
 
 
DATE       DATE 
 
PLACE                                                                     PLACE 
 
 
  iv
ACKNOWLEDGEMENTS 
 I express my deep sense of gratitude and indebtedness to my 
respected teacher and guide, PROF P RAGUMANI M.S., Professor, 
Department of General Surgery, MMC & RGGGH, whose valuable 
guidance and constant help have gone a long way in the preparation of 
this dissertation. 
 I acknowledge my sincere and heartfelt thanks with gratitude to  
S DEIVANAYAGAM., Professor and Head, Department of General 
Surgery, MMC & RGGGH, CHENNAI for his constant help, advice 
and management. 
 I express my sincere and heartfelt gratitude to my former chiefs 
PROF G SIVAKUMAR  M.S.,   and   PROF A PERIASAMY M.S., 
for their clinical classes and lectures and whose valuable guidance and 
constant help have gone a long way in the preparation of this dissertation. 
 I am also thankful to Assistant Professors, DR N SELVARAJ,  
DR MADHIVADANAM,  DR M PARIMALA  for their timely 
suggestions. 
 I express my thanks to the Director & Dean, Madras Medical 
College and RGGGH, CHENNAI, for allowing me to utilise the 
resources of the college and hospital for this study. 
  v
 I express my thanks to all of the staff members of Department of 
General Surgery, and all my post-graduate colleagues and friends for 
their help during my study and preparation of this dissertation and also 
for their cooperation. 
 I always remember my parents, for their everlasting blessings and 
encouragement. 
 Lastly, I express my thanks to my patients without them this study 
would not have been possible. 
 
 
Date                                                                DR M B SRIDEV 
Place                                                     PG IN GENERAL SURGERY 
                                                                MMC & RGGGH, CHENNAI 
 
  vi
LIST OF ABBREVIATIONS 
AGES  --  Age, grade of tumour, extent of tumour, size 
AMES  --  Age, metastatic disease, extra thyroidal extension, size 
ATC   --  Anaplastic thyroid cancer 
DAMES  --  DNA content, age, metastatic disease, extra thyroidal 
   extension, size 
DFS   --  Disease free survival 
FNAC  --  Find Needle Aspiration Cytology 
MACIS  --  Metastasis, age, completeness of surgery, invasion, 
   tumor 
MALT  --  Mucosa associated lymphoid tissue 
MEN   --  Multiple endocrine neoplasia 
MNG  --  Multi nodular goiter 
MTC   --  Medullary thyroid carcinoma 
NHL   --  Non-Hodgkin’s lymphoma 
PS   --  Prognostic score 
PTC   --  Papillary thyroid carcinoma 
RAI   --  Radioactive iodine 
RLN   --  Recurrent laryngeal nerve 
SNT   --  Solitary nodule thyroid 
Tg   --  Thyroglobulin 
TSH   --  Thyroid stimulating hormone 
  vii
ABSTRACT 
BACKGROUND AND OBJECTIVES 
 Thyroid cancer is overwhelmingly the most common type of 
endocrine malignancy accounting for majority of death due to endocrine 
cause. It is a heterogenous group of tumours that show considerate 
variability in histological appearance, in biological behaviour. Clinically 
it presents as any other benign condition of thyroid in its early stages. So 
success in treatment of this condition lies largely upon early diagnosis 
and appropriate management. Hence this study is done to evaluate the 
modes of presentation, incidence of various pathological types, accuracy 
of FNAC in the diagnosis and surgical management. 
METHODOLOGY 
             Patient presenting with sign and symptoms of carcinoma thyroid, 
who were clinically evaluated and confirmed by FNAC were chosen for 
the study. Patients less than 12 years of age and those who were 
previously treated for any other thyroid ailments were excluded from the 
study. 
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RESULTS 
          The occurrence of carcinoma thyroid is  maximum in 4th decade, 
female patients outnumbering males. FNAC was found to be simple, cost 
effective and reliable investigation with overall diagnostic accuracy of 
98%. Most of the well differentiated carcinomas were categorised into 
low risk group of AMES classification. 
INTERPRETATION AND CONCLUSION 
 FNAC is a practical and accurate investigation that provides tissue 
diagnosis. The overall approach in management of thyroid malignancy is 
multi modal comprehensive therapy which is mainly dominated by 
surgical treatment. The extent of surgery depends on clinical staging, 
cytology and risk categorisation. 
KEY WORDS: Thyroid carcinoma; Papillary carcinoma; FNAC 
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INTRODUCTION 
 Thyroid cancer is overwhelmingly the most common type of 
endocrine malignancy, accounting for majority of deaths due to endocrine 
cancers. The majority of the patients with carcinoma of the thyroid have 
differentiated cancer varying in history from a pure papillary carcinoma 
to a follicular carcinoma and in most instances mixed papillary and 
follicular variants. Differentiated carcinoma of the thyroid gland is most 
prevalent in young adults with a female to male ratio of 2:1. 
 Cancer of the thyroid gland represents a spectrum of different 
histological entities with diverse clinical behaviour. Generally there is a 
very low progression from differentiated carcinoma to anaplastic 
carcinoma. However, this transition takes decades to takes place in most 
instances. The clinical evaluation of thyroid nodule is a common problem 
confronting the clinicians. The vast majority of such nodules are benign, 
but such a thyroid swelling may harbour malignancy demands prompt 
and accurate diagnosis. The natural history of thyroid carcinomas allows 
the surgeon to perform a more prolonged and thoughtful preoperative 
workup and evaluation. 
 Appropriate management is essential to achieve the optimal 
therapeutic success. The fine needle aspiration cytology is now the corner 
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stone of investigation for many of these patients and evaluation and 
subsequent treatment usually involve assessment by a multidisciplinary 
team fully conversant in all aspects of thyroid cancer therapy. The clinical 
management of the well-differentiated thyroid carcinomas rests on 
retrospective studies and individual clinical experience. 
             Finally, there is a great variability in the duration of follow up in 
these relatively slow growing lesions. This is a time bound study of cases, 
which presented with thyroid carcinoma to MADRAS MEDICAL 
COLLEGE AND RGGGH, CHENNAI. 
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OBJECTIVES 
1.  To study the clinical presentation of  thyroid malignancies. 
2.  To study the relative incidence of various pathological types of 
thyroid malignancies. 
3.  Correlation of FNAC with HPE. 
4.  To study the various surgical modes of management of thyroid 
malignancies. 
 
 
 
 
 
 
  4
REVIEW OF LITERATURE 
 The name thyroid is derived from the Greek description of a shield-
shaped gland in the anterior aspect of the neck (thyreoides). Andres 
Vasalieus (1514-1564 A.D.), who is credited as the “Father of Anatomy” 
gave the first description of thyroid gland. Classic anatomic descriptions 
of the thyroid were available in the 16th and 17th centuries, but the 
function of the gland was not well understood. By the 19th century, 
pathologic enlargement of the thyroid, or goiter, was described. Iodine-
rich seaweed was used to treat this condition. Direct surgical approaches 
to thyroid masses had frighteningly high complication and mortality rates. 
 In the late 19th century, two surgeon-physiologists revolutionized 
treatment of thyroid diseases. Theodor Billroth and Emil Theodor 
Kocher established large clinics in Europe and, through development of 
skilled surgical techniques combined with newer anaesthetic and 
antiseptic principles, provided surgical results that proved the safety and 
efficacy of thyroid surgery for benign and malignant problems. As a 
result of his pioneering developments in the understanding of thyroid 
physiology, Kocher received the Nobel Prize in 1909. 
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 The 20th century started with the contributions of Kocher and 
Billroth. In rapid succession, the understanding of altered physiology, 
including hypothyroidism, hyperthyroidism, and thyroid cancer, and 
advances in imaging, epidemiology, and most recently, minimally 
invasive diagnostic and surgical techniques have taken place. These 
advances have allowed the diagnosis and treatment of thyroid diseases to 
become rapid, cost-effective, low-morbidity procedures. 
 Duffy 1950 reported the link between child irradiation to head and 
neck and occurrence of thyroid carcinoma as radiation was routinely used 
for therapy of acne, tonsils, enlarged thymus. By 1960, radiation therapy 
for benign condition was abandoned.  FNAC of thyroid was first 
described in the 1930’s by Martin and Ellis. 
 In 1950, the technique of FNAC was popularized in Scandinavia. It 
is Zajieek, the first pathologist to embrace FNAC in collaboration with 
Franzen at the Karolinska hospital defined the precise diagnostic criteria 
and determined the diagnostic accuracy. 
 At Johns Hopkins University Hospital, William S. Halsted 
revolutionized surgical treatment and education and made an enormous 
contribution to the operative treatment of both the thyroid and parathyroid 
glands. Since then a number of important advances have been made in the 
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diagnosis and management of patients with thyroid tumors, including the 
development of antithyroid drugs, fine needle aspiration biopsy, 
radioiodine treatment, and various imaging modalities. 
PIONEERS IN THYROID SURGERY 
 
FIG 1:  THEODORE BILLROTH{1829-1894} 
 
FIG 2:   EMIL THEODORE KOCHER{1841-1917} 
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EMBRYOLOGY 
 The thyroid gland arises as an out pouching of the primitive foregut 
around the third week of gestation. It originates at the base of the tongue 
in the vicinity of the foramen caecum. Endoderm cells in the floor of the 
pharyngeal anlage thicken to form the median thyroid anlage. During its 
descent the median anal age remains connected via thyroglossal duct. 
Paired lateral anlages originate from the fourth branchial pouch and fuse 
with the median anal age at fifth week of gestation. Thyroid follicles are 
initially apparent by eight weeks and colloid formation begins by the 11th 
week of gestation. 
SURGICAL ANATOMY AND RELATIONSHIPS 
 The adult thyroid gland is brown in colour and firm in consistency, 
and is located posterior to the strap muscles. The normal thyroid gland 
weighs approximately 20 g, but gland weight varies with body weight and 
iodine intake. The thyroid lobes are located adjacent to the thyroid 
cartilage and connected in the midline by an isthmus that is located just 
inferior to the cricoid cartilage. A pyramidal lobe is present in about 50% 
of patients. The thyroid lobes extend to the mid thyroid cartilage 
superiorly and lie adjacent to the carotid sheaths and sternocleidomastoid 
muscles laterally. The strap muscles (sternohyoid, sternothyroid, and 
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superior belly of the omohyoid) are located anteriorly and are innervated 
by the ansacervicalis (ansahypoglossi). The thyroid gland is enveloped by 
a loosely connecting fascia that is formed from the partition of the deep 
cervical fascia into anterior and posterior divisions. The true capsule of 
the thyroid is a thin, densely adherent fibrous layer that sends out septa 
that invaginate into the gland, forming pseudolobules. The thyroid 
capsule is condensed into the posterior suspensory or Berry's ligament 
near the cricoid cartilage and upper tracheal rings. 
BLOOD SUPPLY 
 The supply and drainage of blood to and from the thyroid involves 
two pairs of arteries, three pairs of veins, and a dense network of 
connecting vessels that mesh throughout the capsule of the gland. The 
superior thyroid artery begins as the first branch of the external carotid 
artery in 80% of individuals and from the common carotid artery in the 
remainders. The superior thyroid artery goes to the superior pole of the 
gland where it divides to lie in the anterior and posterior surface of the 
lobe. The superior thyroid artery usually lie posterolaterally and parallel 
to the external branch of the superior laryngeal nerve. It is surgically 
significant that there is perhaps 1 cm of the superior thyroid artery 
between the gland and the anterior take off of the external laryngeal 
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nerve. This space allows safe clamping of the vessel. The inferior thyroid 
arteries branch directly from the thyrocervical trunk, and they are the only 
structures in the lower neck to cross the long axis of the common carotid 
artery deep to the vessel. The artery usually gives off one or two 
branches, one directed cephalically to the superior parathyroid gland and 
another inferiorly to the inferior parathyroid gland. Because this blood 
supply to the delicate parathyroid gland is critical to their function, 
ligation of the inferior thyroid artery should take place beyond these take 
off sites. A variable (3%) a third artery, thyroid ima, artery arise from 
brachio cephalic artery or aortic ach and ascends anterior to trachea. 
 NERVES  
 The thyroid gland is closely associated with two nerves- the 
recurrent laryngeal and the external laryngeal nerves. The right recurrent 
laryngeal nerve leaves the vagus at the base of the neck, loops around the 
subclavian artery, and then extends into the thyroid bed 2 cm lateral to the 
trachea. The left recurrent laryngeal nerve has somewhat different course 
than the right; it leaves the vagus nerve at the level of the aortic arch and 
passes inferior and posterior to the arch, lateral to the ductus arteriosus. It 
then passes posterior to the carotid sheath and into the thyroid bed, where 
it is closer to and parallel to the tracheoesophageal groove than its 
  10
counterpart on the other side of the neck. Recurrent nerve run behind the 
artery in 53% on right and 69% on left and run anterior to artery in 37% 
on right and 24% on left. It is easily susceptible to stretching when the 
thyroid lobe is retracted anteriorly near the berry ligament. Unusually the 
non-recurrent laryngeal nerve can arise directly from the vagus and pass 
directly into the thyroid this non-recurrent anatomy is found in 1-1.5% of 
patients. Even more infrequently, there may be recurrent and non-
recurrent laryngeal nerves. These two nerves usually join in a position 
beneath the lower pole of the thyroid. The superior laryngeal nerves arise 
from the vagus nerve at the base of the skull and descend towards the 
superior pole of the thyroid along the internal carotid artery. The smaller 
external branch travels along the lateral surface of the inferior pharyngeal 
constrictor muscle and usually descends anteriorly and medially along 
with the superior thyroid artery. Within 1 cm of the superior thyroid 
artery’s entrance into the thyroid, the nerve takes a medial course and 
enters into the cricothyroid muscle. The nerve is not usually visualized 
during surgery as it has already entered the inferior pharyngeal muscle 
fascia. This nerve is at risk of severed or entrapped if the superior pole 
vessels are ligated too above the superior pole of the thyroid. 
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 Cernea and colleagues proposed a classification system to 
describe the relationship of this nerve to the superior thyroid vessels . The 
type 2a variant, in which the nerve crosses below the tip of the thyroid 
superior pole, occurs in up to 20% of individuals and places the nerve at a 
greater risk of injury. 
LYMPHATIC  DRAINAGE 
 The thyroid gland is endowed with an extensive network of 
lymphatics. Intra glandular lymphatic vessels connect both thyroid lobes 
through the isthmus and also drain to perithyroidal structures and lymph 
nodes. Regional lymph nodes include pretracheal, paratracheal, 
perithyroidal, RLN, superior mediastinal, retropharyngeal, esophageal, 
and upper, middle, and lower jugular chain nodes. These lymph nodes 
can be classified into seven levels as depicted in . The central 
compartment includes nodes located in the area between the two carotid 
sheaths, whereas nodes lateral to the vessels are present in the lateral 
compartment. Thyroid cancers may metastasize to any of these regions, 
although metastases to submaxillary nodes (level I) are rare (<1%). There 
also can be "skip" metastases to nodes in the ipsilateral neck. 
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Major 
Middle jugular nodes: level III 
Lower jugular nodes: level IV 
Posterior triangle nodes: level V 
Lesser 
Pretracheal and paratracheal nodes: level VI 
Superior mediastinal nodes: level VII 
Fig 3 -Thyroid gland { anterior view} 
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Fig 4 Thyroid anatomy-- nerves 
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Fig 5 Gross Anatomy-- Thyroid Gland 
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Fig 6 Head And Neck Lymphatics 
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EPIDEMIOLOGY 
           The Indian Council of Medical Research established the National 
Cancer Registry Program, and the NCRP has collected the data of more 
than 3,00,000 cancer patients between the periods 1984 and 1993. Among 
these patients, the NCRP noted 5614 cases of thyroid cancer, and this 
included 3617 females and 2007 males. The six centers involved in the 
studies were at Mumbai, Delhi, Thiruvananthapuram,  Dibrugarh, 
Chandigarh, and Chennai. Among them, Thiruvananthapuram had the 
highest relative frequency of cases of thyroid cancer among all cancer 
cases enrolled in the hospital registry, 1.99% among males and 5.71% 
among females. The nation widerelative frequency of thyroid cancer 
among all the  cancer cases was 0.1%–0.2%. 
           The age-adjusted incidence rates of thyroid cancer per 100,000 are 
about 1 for males and 1.8 for females as per the Mumbai Cancer Registry, 
which covered a population of 9.81 million subjects. The histological 
types of thyroid cancer were studied in a Hospital Cancer Registry of 
1185 “new cases” of thyroid cancer. The commonest cancer type was 
papillary, followed by follicular cancer. 
           Thyroid cancer is less common in children than  in adults but still 
accounts for 1.4% of childhood malignancies.20 The incidence of thyroid 
  17
cancer in children younger than 15 years is approximately 0.5 per million 
per year, with a rapid rise occurring after the age of 5. In reality because 
of the fact that many thyroid cancers never become clinically apparent 
and as such are never diagnosed, the true incidence is not known.Women 
are affected more than men the ratio is somewhere around 1:1.6 to 1:3.15 
Even though the overall incidence of differentiated thyroid cancer is 
morecommon in women than in men, a nodule in a man is more likely to 
be malignant than in a woman. 
ETIOLOGY 
1. Radiation exposure: 
 Exposure to radiation is the only proved thyroid carcinogen.This 
was first recognized by Duffy and Fitzgerald in 1950. A 10 to 20 year 
postradiation latency period was reported earlier but this has not been 
noted in the pediatric thyroid cancer cases that have resulted from the 
Chernobyl nuclear disaster in the Ukraine in 1986, where there has been a 
dramatic increase in such cancers as early as 1989. In contrast to external 
radiation, there is little evidence to suggest that internal radiation from 
I131 used for therapeutic or diagnostic medical purposes causes thyroid 
cancer in humans. 
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2. Hereditary factors: 
 Among the thyroid malignancies, the medullary carcinoma is 
familial in 10% to 30% of cases. Patients with familial version have 
medullary carcinoma as an autosomal dominant trait in one of the three 
distinct clinical syndromes. 
i.  Isolated familial medullary thyroid carcinoma (FMTC) 
ii.  Multiple endocrine neoplasia syndrome type 2A (MEN 2A) 
iii.  Multiple endocrine neoplasia syndrome type 2B (MEN 2B) 
 Patients with Cowden’s syndrome and Gardner’s syndrome have 
an increased risk of benign and malignant neoplasms of the thyroid. 
About 6% of the patients with differentiated thyroid cancers have familial 
non-medullary thyroid cancer. Papillary thyroid cancer accounts for 90% 
of familial non-medullary thyroid cancer. 
3. Family History: 
 Thyroid cancer is a risk factor for the development of both 
medullary and nonmedullary thyroid cancer. Familial medullary thyroid 
cancer occurs in association with other tumours as part of multiple 
endocrine neoplasia 2 (MEN 2) syndromes. Non-medullary thyroid 
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cancer can occur in association with known familial cancer syndromes 
such as Cowden’s syndrome, Werner’s syndrome, Gardner’s syndrome 
and FAP. Papillary thyroid cancer accounts for 90% of familial non 
medullary thyroid cancer. 
4. Thyroid stimulating hormone elevation: 
 An increased risk of thyroid cancer is seen in patients with chronic 
elevation of TSH. Animal experiments indicate that prolonged TSH 
stimulation can cause thyroid cancer. Even though it is not clear in 
humans, increased TSH though not being sufficient to cause thyroid 
cancers may stimulate its growth once present. 
5. Chronic Lymphocytic Thyroiditis: 
 Thyroid lymphoma most often occurs against a background of 
autoimmune lymphocytic thyroiditis (Hashimotos disease). 
6. Solitary thyroid nodule: 
 Presence of solitary thyroid nodule is also a risk factor for 
malignancy. The incidence of malignancy with in a clinically apparent 
SNT is approximately 5-10%. If imaging investigations show the nodule 
to be truly solitary, then the likelihood of it being malignant increases to 
about 20%. 
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CLASSIFICATION OF THYROID MALIGNANCIES 
PRIMARY 
1. Follicular epithelial cells 
Differentiated 
Papillary carcinoma 
Follicular carcinoma 
Undifferentiated 
Anaplastic carcinoma 
2. Parafollicular cells 
Medullary carcinoma 
3. Lymphoid cells 
Lymphoma 
SECONDARY 
1. Metastatic 
2. Local infiltration 
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PATHOLOGY AND NATURAL HISTORY 
PAPILLARY CANCER –THYROID 
  The typical PTC on physical examination is firm with an irregular 
border, has a white colour, and may contain micro calcifications. It can be 
classified as occult (less than 1.5 cm in greatest dimension), intrathyroidal 
(larger than 1.5 cm but confined to the gland), and extrathyroidal 
(extending beyond the capsule to involve the surrounding viscera). At the 
time of presentation, upto 80%-90% of the primary lesions are confined 
to the gland. Encapsulation of the tumour is seen in 10% of the cases. 
Tumour multicentricity is seen in 20% to 30% of cases in most of the 
studies. In 1971 Woolner described papillary cancer seen by light 
microscopy: “The typical histological picture is a mixture of papillary 
excrescences and neoplastic follicles containing varying degrees of 
colloid. The percentage of papillary and follicular elements is varied. The 
nucleus is hypodense with large areas that appear empty and are 
apparently devoid of chromatin. Consequently, the nucleus appear opaque 
and are given many names including “clear”, “watery”, “pale”, or the 
most imaginative 
 “Orphan Annie Eyes”. Consequently the diagnosis of PTC is based 
on a constellation of findings. In particular, papillae projecting into open 
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spaces, as well as clear nuclei with prominent nuclear grooves are all 
important features of the diagnosis. Another important feature is the 
presence of psammoma bodies (Greek: psammoma – sand) which are 
laminated calcific areas. They are seen in 50% of cases in most series. 
Although the etiology is unclear it is believed to represent the remains of 
the dead papillae and are quiet specific for PTC and are rarely seen in 
other thyroid lesions. 
Morphological variants of papillary thyroid carcinoma 
Variants with similar clinical behaviour 
 Follicular 
 Micropapillary 
 Encapsulated Solid 
 Solid/Trabecular 
Variants with more aggressive behaviour 
 Tall cell 
 Diffuse sclerosing 
 Columnar 
 Oxyphil { hurthle cell } 
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 The propensity for papillary cancer to spread in the lymphatics 
within and outside the gland is striking. 5-10% of patients present with 
distant metastases at some time in course of the disease. The natural 
prognosis of the metastatic cancer seems to be volume related. It is worse 
in patients with bone, lung and CNS metastases. The tall cell variant has a 
worse prognosis in all age groups. 
 
 
 
 
 
 
  24
Fig 7 :PAPILLARY CA THYROID --
GROSS
 
Fig 8: PAPILLARY CA THYROID -- MICROSCOPIC 
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FOLLICULAR CARCINOMA OF THYROID (FTC) 
 Follicular thyroid cancer accounts for approximately 10–15 % of 
thyroid malignancies. Follicular cancers are encapsulated lesions and are 
very difficult to differentiate from its benign counterpart follicular 
adenomas. They are characterized microscopically by large nuclei, 
frequent and/or atypical mitotic figures, vascular invasion, and distant 
metastases. In contrast to papillary carcinoma intrathyroidal multifocal 
disease rarely occurs in follicular cancers. Instead these lesions are 
usually solitary, encapsulated and have a microfollicular histologic 
pattern. The findings that constitute malignancy are not cytologic but 
instead are histological features like transcapsular invasion and 
microvascular invasion of the vessels along the thyroid capsule. Lymph 
node involvement is unusual and it occurs late in the course of the 
disease. Follicular cancers are divided into “minimally invasive” and 
“widely invasive”. The minimally invasive forms are grossly 
encapsulated and the diagnosis depends upon the presence of vascular or 
capsular invasion: The widely invasive form is characterized by 
widespread infiltration of the blood vessels or the adjacent thyroid tissue. 
Tumours that represent a mixed form of papillary and follicular features, 
showing signs of follicular differentiation and also signs of papillary 
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cancer should clinically regarded as papillary rather than follicular 
cancers 
MORPHOLOGICAL VARIANTS OF FOLLICULAR THYROID  
CARCINOMA 
• Hurthle cell variant (Oxyphil or 
Oncocyticcarcinoma) 
• Insular cell variant 
 30% to 50% of Hurthle cell carcinomas are associate with lymph 
node metastases, compared with 5% to 10% of follicular cancers.The 
Hurthle cell variant, unlike other follicular cells does not take up 
radioactive iodine. This variant occurs particularly in adult women and is 
usually solid, well vascularised and well encapsulated. The insular 
tumours were so named because the clusters of cells within it contain 
small follicles that resemble the pancreatic islet cells. Insular thyroid 
cancer is a more aggressive malignancy and is perceived to behave less 
favourable than the papillary and follicular cancers. 
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FIG 9:FOLLICULAR CA THYROID{GROSS} 
 
 
  FIG 10 :FOLLICULAR CANCER THYROID { MICROSCOPIC} 
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ANAPLASTIC CARCINOMA OF THE THYROID (ATC) 
 Anaplastic carcinoma is a devastating disease that usually 
overcomes thehostin a matter of months, sometimes even weeks. They 
represent 5% to 14% of thyroid malignancies.The median age of onset of 
ATC is consistently in the seventh decade of life and the disease is 
characterized by female preponderance ranging from 55% to 77%. The 
anaplastic component is composed of varying proportions of spindle, 
polygonal and giant cells. In general, the lethality of anaplastic cancer 
should not be underestimated, even when minimal in size amid a 
background of predominately differentiated cancer. The natural history of 
this cancer is characterized by rapid and massive locoregional growth, 
dysphagia, Svsyndrome and finally asphyxiation or exsanguination. 
MEDULLARY CARCINOMA OF THE THYROID (MTC) 
 These malignancies are derived from the non epithelial 
parafollicular or the C cells which have the ability to synthesize and 
secrete calcitonin. MTC typically arise from the upper portion of the 
thyroid where the C-cells are concentrated. These cell are derived from 
the neural crest and are therefore of neuro ectodermal origin. Hence the 
medullary carcinomas have histological and cytological features typical 
of other neuro endocrine tumours such as carcinoid tumours, pancreatic 
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islet cell tumours and pheochromocytomas. They occur in two basic 
forms, sporadic and familial. The sporadic type make up 70% to 90% of 
the total and the familial 10% to 20%. FNAC yields presumptive clues to 
the diagnosis of MTC. Spindle shaped or triangular cells with dendritic 
extensions are highly suggestive of MTC. Although amyloid may be 
presumptively identified in Papanicolau stains, it is confirmed by 
restaining with Congo red. On gross examination it is firm, solid, grayish, 
or pale brown welldemarcated from the surrounding tissues 
Microscopically the typical appearance is that of polyhedral cells 
arranged in sheets or irregular trabeculae. In familial cases there are often 
microscopic foci of  C cell hyperplasia, or microscopic medullary 
carcinoma in areas of normal parenchyma, thus demonstrating 
multicentric tumour origin. 
PHENOTYPES RELATED TO MUTATION OF THE RET 
PROTO-ONCOGEN MEN 2A (60%) 
Medullary thyroid carcinoma                        100 
Pheochromocytoma                                     10-60 
Hyperparathyroidism                                      5-20 
MEN 2B (5%) 
Medullary thyroid carcinoma                         100 
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Pheochromocytoma                                        50 
Marfanoid habitus                                          100 
Mucosal neuromas (gut) and                         100 
ganglioneuromatosis 
FMTC (35%) 
Medullary thyroid carcinoma 100 
 {MEN 2A, multiple endocrine neoplasia type 2A; MEN 2B, 
multiple endocrine neoplasia type 2B; FMTC, familial medullary thyroid 
carcinoma. } 
CLINICAL PRESENTATION OF THYROID CARCINOMAS 
1. Thyroid swelling 
 Thyroid cancer most commonly presents as a single neck mass 
noted incidentally by the patient or the physician. A thyroid mass in a 
child no matter its size or consistency is highly suspicious of malignancy. 
Regardless of the sex, the mass in advanced years is likely to be 
malignant. Though many women develop thyroid cancer than in men, any 
given nodule in a man is more likely to be malignant. Although such 
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words as hard with fixation can apply to a mass associated with 
thyroiditis, these features must be viewed with suspicion for malignancy. 
The opposite must not be assumed, however; soft masses with no fixation 
to the surrounding tissues are not necessarily benign. Rapid enlargement 
can be deceptive because of the tendency for intralesional hemorrhage. 
On the other hand, the relentless and rapid growth that can be seen in 
anaplastic carcinoma is so impressive that its ominous nature is quiet 
obvious. Cystic lesions are more likely benign, but cystic carcinomas do 
occur. Solid lesions have a 21% risk of malignancy, cystic 7% and mixed 
lesions had a risk of 12%. 5% to 10% of multiple nodules and 10% to 
20% of solitary nodules are malignant. 
2. Cervical lymphadenopathy 
          In case of papillary carcinoma which is known for its lymphatic 
spread the patient present with cervical lymphadenopathy alone in 20% of 
cases and a mass in the thyroid with cervical lymphadenopathy in 13% of 
cases. Children and young adults more often have palpable nodal 
metastases. Most studies report a 30% to 40%incidence of cervical nodal 
metastasis when therapeutic nodal dissections were performed. In 
medullary carcinoma metastases are mostly found in the neck and 
mediastinal lymph nodes, and may calcify. Sporadic cases of MTC are 
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more prone for lymph nodal spread than the familial cases. In the 
presence of a seemingly normal thyroid gland, a lateral neck mass with 
biopsy proven thyroid tissue was previously misconceived to represent an 
embryonic nest of thyroid tissue and erroneously termed “lateral aberrant 
thyroid”. This presentation is now considered to be caused by metastatic 
well differentiated thyroid carcinoma from an occult primary within the 
gland until proved otherwise. 
3. Symptoms related to the tumour growth 
        These symptoms may infrequently precede or occur simultaneously 
with the development of a nodule, include hoarseness, dyspnoea and 
dysphagia, reflecting local infiltration of the recurrent laryngeal nerve, 
the trachea and the esophagus respectively. Horner’s syndrome associated 
with a thyroid mass usually represents an ominous circumstance. Large 
multi nodular goiters with or without substernal extension can cause 
tracheal shift or impingement and alteration of the airway. Local 
compressive symptoms are a rule in case of anaplastic carcinoma and can 
include stridor, dysphagia, dyspnoea, hoarseness, weight loss and even 
superior vena cava syndrome. 
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4. Symptoms related to distant metastases 
         Among the thyroid malignancies anaplastic carcinomas are quiet 
likely to have a distant metastasis which are usually pulmonary but can 
also involve bone, brain and soft tissues. Distant foci of the tumour are 
seen in 20% to 50% of patients. Most distant metastases are found in the 
lung, liver and bone.They are found in more than75% who die from 
thyroid carcinoma and lung metastasis account for almost 50%tumour 
related deaths. 
5. Symptoms related to hormonal derangement 
 Thyroid cancer can present with hyperthyroid features with the 
incidence currently at about 5% to 10% in patients with Grave’s disease. 
Papillary carcinoma accounts for 75% of thyroid cancers associated with 
Grave’s disease.61 Patients who present with clinical evidence of thyroid 
cancer and have Grave’s disease have more aggressive tumours, whereas 
patients with occult thyroid cancers who are treated for Grave’s disease 
have an excellent prognosis. Diarrhea has been reported in 20% to 30% 
of cases of sporadic MTC at presentation often in patients with extensive 
disease. The underlying mechanism is still to be clarified. Prostaglandins, 
Vaso active intestinal polypeptide, Calcitonin gene related peptide and 
Seratonin have all been suggested as mediators of this symptom. 
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Although rare, concomitant Cushing’s syndrome is the most striking 
presentationof sporadic MTC in some cases. This unusual phenomenon is 
explained by the common precursor of ACTH and calcitonin. When 
cortisol production is excessive and the tumour burden is too large for 
resection, bilateral adrenalectomy is the last resort. 
LABORATORY EVALUATION 
BLOOD INVESTIGATIONS 
Serum TSH 
 TSH levels can be measured accurately down to very low serum 
concentrations with an immune chemiluminometric assay. When the 
serum TSH level is in the normal range, measuring the T3 and T4 levels 
is redundant. Interpretation of deranged TSH levels, however, depends on 
knowledge of the T3 and T4 values . In the euthyroid state, T3, T4 and 
TSH levels will all be within the normal range. Florid thyroid failure 
results in depressed T3 and T4 levels, with gross elevation of the TSH. 
Incipient or developing thyroid failure is characterised by low normal 
values of T3 and T4 and elevation of TSH. In toxic states the TSH level is 
suppressed and undetectable. 
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Thyroxine (T4) and tri-iodothyronine (T3) 
 There are transported in plasma bound to specific proteins (TBG). 
Only a small fraction of the total (0.03% of T4 and 0.3% of T3) is free 
and physiologically active. Assays of total hormone for both are now 
obsolete because of the confounding effect of circulating protein 
concentrations, influenced by the level of circulating oestrogen and the 
nutritional state. Highly accurate radio immunoassays of free T3 and free 
T4 are now routine. T3 toxicity (with a normal T4) is a distinct entity and 
may only be diagnosed by measuring the serum T3, although a 
suppressed TSH level with a normal T4 may suggest the diagnosis. An 
appropriate combination to establish the functional thyroid status at initial 
assessment is measurement of serum TSH and assay of anti-thyroid 
antibodies, supplemented by free T4 and T3 evaluation when TSH is 
abnormal. 
Thyroid auto antibodies 
 Serum levels of antibodies against thyroid peroxidase (TPO; 
previously referred to as thyroid microsomal antigen) and thyroglobulin 
are useful in determining the cause of thyroid dysfunction and swellings. 
Autoimmune thyroiditis may be associated with thyroid toxicity, failure 
or euthyroid goitre. Levels above 25 units ml–1 for TPO antibody and 
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titres of greater than 1:100 for anti-thyroglobulin are considered 
significant, although a proportion of patients with histological evidence of 
lymphocytic (autoimmune) thyroiditis are seronegative. The presence of 
antithyroglobulin antibody interferes with assays of serum thyroglobulin 
with implications for the follow-up of thyroid cancers. 
Calcitonin 
 Of all the blood products, the plasma calcitonin has the most direct 
diagnostic value in determining the nature of the thyroid mass. This 
polypeptide is produced exclusively by the C-cells, and its measurement 
is sensitive, accurate and consistent to a degree that it is possible to 
diagnose C-cell hyperplasia or medullary cancers as small as 1 mm in 
diameter. Calcitonin levels are elevated in almost all patients with MTC. 
However in those patients who do have a normal baseline values, 
detections of microlesions or C-cell hyperplasia associated with MEN2A 
or MEN2B can be accomplished with a pentagastrin or a calcium 
stimulation of calcitonin. Normal calcitonin levels < 10 pg/ml. A 
stimulated value of < 30 pg/ml is considered normal and a value greater 
than 100 pg/ml is abnormal 
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Thyroglobulin 
 Serum thyroglobulin is reflective of three factors: the mass of 
thyroid tissue present, the presence of injury or inflammation of the 
gland, which allows leakage of Tg, and the degree of stimulation of the 
TSH receptor. Thyroglobulin is present in normal serum in concentrations 
of 20 to 40 ng/ml, but elevation above this offers no specific information. 
Thyroiditis and even hyperthyroidism may be responsible for an 
abnormal high thyroglobulin. It should be noted that, eventhough 
diagnostic sensitivity has not been described, a thyroglobulin level of 
more than 10 times the upper limit of normal is highly suggestive of 
cancer. Serum thyroglobulin levels > 2 ng/ml after thyroidectomy 
indicates presence of metastatic disease and a rise in S. thyroglobulin in a 
patient with known metastases indicates progression of disease. 
Thyroglobulin levels of > 60 ng/ml suggests thyroid cancers.  
Genetic testing 
 Genetic testing is available for family members at risk for 
developing medullary cancer. The ret protooncogene encodes a protein 
receptor, tyrosine kinase. Mutations of ret are associated in 95% of 
hereditary medullary thyroid cancers, MEN 2A, MEN 2B and FMTC. 
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Other blood tests 
 Patients with MEN 2A and 2B have associated pheochromocytoma 
and hyperparathyroidism and hence those with family history or those 
with features of either of these must be investigated for these disorders 
also. 
FINE NEEDLE ASPIRATION CYTOLOGY{ FNAC } 
 FNA has revolutionized the management of thyroid nodules, 
providing an extremely sensitive and cost-effective method of detecting 
thyroid malignancies. The impact this procedure has had on clinical 
practice is reflected by a reduction of the total number of thyroid surgical 
procedures performed, a greater proportion of malignancies removed at 
surgery, and an overall reduction in the cost of managing patients with 
thyroid nodules. The accuracy of cytologic diagnosis from FNA ranges 
from 70% to 97% and is highly dependent on both the skill of the 
individual performing the biopsy and the cytopathologist interpreting it.  
In most instances, the cytology report will be one of the following three: 
          1. Probably benign nodule, when the material is composed largely 
of colloid, histiocytes and few normal looking follicular cells. This will 
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be indication for a conservative approach unless the clinical data suggests 
otherwise. 
          2. Follicular neoplasm; when cellularity higher than that found in 
the usual hyper plastic nodule, but the nuclear features of papillary cancer 
are absent. The diagnosis of Hurthle cell neoplasm usually falls in the 
category.71 The presence of highly hyper chromatic nuclei, micro 
follicular or solid pattern, scanty colloid and necrotic debris suggest the 
prevalence of poorly differentiated cancer. The diagnosis of follicular 
neoplasm is an indication for removal of the nodule, unless this is 
contraindicated for medical reasons. 
           3. Papillary cancer, when the characteristic cyto architectural 
features of this tumor type are present, such as papillary fronds, 
psammomma bodies, nuclear pseudo inclusions, and nuclear grooves. It 
should be remembered that the ground glass nuclear feature is usually not 
apparent in cytological preparations; even when prominent in tissue 
sections. Concerning the follicular variant of papillary carcinoma, the 
nuclear change should be particularly well developed. In both the classic 
and the follicular variants of the tumor the colloid often exhibits a 
peculiar streaking and smearing that can be compared with that of a 
bubble gum. The cytological diagnosis of papillary cancer is obviously an 
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indication for therapeutic intervention, even if occasional surgical 
specimen may show only a papillary micro carcinoma. The performance 
of FNA may result in a partial or complete.          
 The malignant potential of follicular neoplasms can rarely be 
determined by cytologic evaluation; thus, the biopsies from such lesions 
are generally classified as suspicious or indeterminate, and most come to 
surgical resection. The cells from follicular adenomas and follicular 
carcinomas appear cytologically identical; only by identifying capsular or 
vascular invasion on histologic specimens can cancer be diagnosed. 
Specimens with predominantly Hurthle cells are treated in the same 
fashion; however, extensive hurthle cell changes can be seen in 
Hashimoto's thyroiditis. Malignancy is found in approximately 20% of 
follicular nodules that are classified as indeterminate on FNA. 
 A variety of molecular markers have been assessed in FNA 
specimens in an attempt to develop more discriminating cytologic sub 
classifications to improve the yield of malignancy found at surgery. 
These markers include telomerase activity, loss of heterozygosity, as well 
as various pattern of protein expression by immunocytochemistry. 
Although there is little doubt that molecular markers will prove useful in 
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the future, currently there is no single or group of markers that has been 
adopted in routine clinical practice. 
THE BETHESDA SYSTEM FOR REPORTING THYROID 
CYTOPATHOLOGY: 
 Recommended Diagnostic Categories 
I. Nondiagnostic or Unsatisfactory 
o Cyst fluid only 
o Virtually acellular specimen 
o Other (obscuring blood, clotting artifact, etc) 
II. Benign 
• Consistent with a benign follicular nodule (includes adenomatoid 
nodule, colloid nodule, etc) 
• Consistent with lymphocytic (Hashimoto) thyroiditis in the proper 
clinical context 
• Consistent with granulomatous (subacute) thyroiditis 
• Other 
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III. Atypia of Undetermined Significance or Follicular Lesion of 
Undetermined Significance 
IV. Follicular Neoplasm or Suspicious for a Follicular Neoplasm 
Specify if Hürthle cell (oncocytic) type 
V. Suspicious for Malignancy 
• Suspicious for papillary carcinoma 
• Suspicious for medullary carcinoma 
• Suspicious for metastatic carcinoma 
• Suspicious for lymphoma 
• Other 
VI. Malignant 
• Papillary thyroid carcinoma 
• Poorly differentiated carcinoma 
• Medullary thyroid carcinoma 
• Undifferentiated (anaplastic) carcinoma 
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• Squamous cell carcinoma 
• Carcinoma with mixed features (specify) 
• Metastatic carcinoma 
• Non-Hodgkin lymphoma 
• Other 
THYROID IMAGING 
ULTRASOUND 
 Ultrasound is helpful in assessing a thyroid nodule. Its advantages 
include portability, cost-effectiveness, and lack of ionizing radiation. It is 
extremely useful in patients who are being managed conservatively 
because it can easily determine whether a nodule has increased in size. 
Ultrasound is used routinely in the office setting and is also available for 
intraoperative evaluation. It has proved highly effective in determining 
the location and characteristics (cystic versus solid) of nodules but is 
unable to accurately predict the diagnosis of solid nodules . The finding 
of a cystic lesion may be reassuring, but such lesions represent a small 
minority of thyroid nodules (1%-5%). Additionally, well-differentiated 
thyroid cancers may have cystic components, although this is very 
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unusual.Ultrasound uses a high-frequency probe in the 7.5- to 12-MHz 
range. Ultrasound devices have become portable enough to allow use in 
the clinic and the operating room. B-mode ultrasonography can be used 
preoperatively or intraoperatively. It is increasingly being used to assist in 
FNA 
Radioisotope Scanning 
 Whereas ultrasound allows anatomic evaluation, radionuclide scans 
allow assessment of thyroid function. Technetium pertechnetate (99mTc) 
is taken up rapidly by the normal activity of follicular cells. It is trapped 
by follicular cells, but not organified. 99mTc has a short half-life and low 
radiation dose. Its rapid absorption allows quick evaluation of increased 
uptake (so-called hot) or hypofunctioning (so-called cold) areas of the 
thyroid. Because screening with 99mTc shows uptake in the salivary 
glands and major vascular structures, interpretation of thyroid pathology 
requires a higher level of expertise. 123I and 131I iodine scintigraphy is 
also used to evaluate the functional status of the gland . Both are trapped 
by active follicular cells and organified. 123I has a shorter half-life (12-
13 hours) and allows a quicker image. Advantages of scanning with 123I 
include a low dose of radiation (30 mrad) and short half-life. 123I is a 
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good choice for evaluating suspected lingual thyroids or substernal 
goiters. 
 131I has a longer half-life (8 days) and emits higher levels of β-
radiation. 131I is optimal for imaging thyroid carcinoma. It is the 
screening modality of choice for the evaluation of distant metastasis. 
Radionuclide scanning demonstrates the function of thyroid nodules as 
hot (excess uptake) or cold (no uptake) in comparison to surrounding 
tissue. Malignancy has been shown to occur in 15% to 20% of cold 
nodules and, additionally, in 5% to 9% of nodules with uptake that is 
warm or hot, thus mandating a continued aggressive approach to 
clinically suspicious nodules, even if they are not cold. 
 Positron emission tomography (PET) with 18F-
fluorodeoxyglucose can be used to provide three-dimensional 
reconstruction images. There is increasing enthusiasm for its use in 
detecting primary and metastatic thyroid cancer. Interestingly, PET scans 
identify occasional so-called thyroid incidentalomas when evaluating 
other solid malignancies. The majority of these findings, however, are not 
malignant. The appropriateness of PET in the workup or follow-up of 
thyroid nodules remains to be firmly established or agreed on. 
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CT and MRI 
 It is fairly well agreed that CT and MRI do not add significantly to 
the workup of uncomplicated thyroid nodules. Either modality, however, 
may be of help in evaluating for local extension in more advanced stages 
of thyroid cancer. CT or MRI is particularly appropriate for a suspicious 
mass (or biopsy-proven cancer) with palpable cervical lymph nodes. 
Additionally, either can be used for postoperative follow-up, particularly 
for suspicion of recurrent disease. Preoperative CT or MRI is advisable 
for larger thyroid masses that show significant tracheal deviation 
suggestive of a substernalgoiter on chest radiographs. 
 CT and MRI are both equally sensitive and specific for the 
evaluation of thyroid masses. Consideration must be given to the use of 
IV contrast for CT evaluation of a possible cancer. The iodine load may 
interfere with postoperative plans for 131I scanning. 
Radiograph: 
 Standard radiographs provide limited information in the evaluation 
of a thyroid mass, and with the exception of identification of metastatic 
lung  disease, provide no specific information. The chest radiograph 
should include the lower neck that the position of the trachea is 
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visualized. This can also suggest  substernal extension of a large goiter. 
When calcifications are seen in the glandand especially if they are 
bilateral bulky and near the junction of the upper two third and the lower 
one third, medullary cancer is suggested. Such calcifications can also be 
seen in metastatic MTC in the cervical nodes. 
Fig11 Thyroid USG      
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Fig 12  CT Scan Thyroid     
 
STAGING OF THYROID CANCER 
TNM Staging -- Primary tumour (T) 
Tx - Primary tumour cannot be assessed. 
T0 - No evidence of primary tumour. 
T1 - Tumour 2 cm or less in greatest dimension limited to the thyroid. 
T2 - Tumour more than 2 cm but not more than 4 cm in greatest 
dimension limited to the thyroid. 
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T3 - Tumour more than 4 cm in greatest dimension limited to the thyroid 
or any tumour with minimal extrathyroid extension. 
T4a - Tumour of any size extending beyond the thyroid capsule to invade 
the subcutaneous soft tissues, larynx, trachea, esophagus or recurrent 
laryngeal nerve. 
T4b - Tumour invades prevertebral fascia or encases the carotid artery or 
mediastinalvessels. 
All Anaplastic carcinomas are T4 tumours. 
T4a - Intrathyroidal anaplastic carcinoma - surgically resectable. 
T4b - Extrathyroidal anaplastic carcinoma - surgically unresectable. 
Regional lymph nodes (N) 
Regional lymph nodes are the central compartment, lateral cervical, 
mediastinal lymph nodes. 
Nx - Regional lymph nodes cannot be assessed. 
N0 - No regional lymph node metastases. 
Nl - Regional lymph node metastases. 
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N1a - Metastases to level 6 (pretracheal, paratracheal and  
prelaryngeal/Delphian lymph nodes). 
N1b - Metastases to unilateral, bilateral or contralateral cervical or 
superior ediastinallymph nodes. 
Distant metastases 
Mx - Distant metastases cannot be assessed. 
M0- No distant metastases. 
M1- Distant metastases. 
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PAPILLARY OR FOLLICULAR CARCINOMA 
Stage Grouping of Papillary / Follicular carcinomas (<45 years) 
Stage 1 Any T Any N M0 
Stage 2 Any T Any N M1 
 
STAGE GROUPING OF PAPILLARY / FOLLICULAR 
CARCINOMAS (>45YEARS) 
STAGE 1 T 1 N 0 M0 
STAGE 2 T 2 N0 M0 
STAGE 3 T3 
T1 
T2 
T3 
N0 
N1A 
N1A 
N1A 
M0 
M0 
M0 
M0 
STAGE 4 A T4A 
T4A 
T1 
T2 
T3 
T4A 
N0 
N1A 
N1B 
N1B 
N1B 
N1B 
M0 
M0 
M0 
M0 
M0 
M0 
STAGE 4 B T4B ANY N M0 
STAGE 4 C ANY T ANY N M1 
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MEDULLARY CARCINOMA --STAGE GROUPING OF 
MEDULLARY CARCINOMAS 
Stage 1 T1 N0 MO 
Stage 2 T2 N0 M0 
Stage 3 T3 
T1 
T2 
T3 
N0 
N1A 
N1A 
N1A 
M0 
M0 
M0 
M0 
Stage 4a T4A 
T4A 
T1 
T2 
T3 
T4A 
N0 
N1A 
N1B 
N1B 
N1B 
N1B 
M0 
M0 
M0 
M0 
M0 
M0 
Stage 4b T4B ANY N M0 
Stage 4c ANY T ANY N M1 
 
ANAPLASTIC CARCINOMA 
All anaplastic carcinomas are considered as stage IV. 
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Stage Grouping of Anaplastic carcinomas 
STAGE 4A T4A ANY N MO 
STAGE 4B T4B ANY N M0 
STAGE 4C ANY T ANY N M1 
 
Survival and Prognostic Features 
 Overall survival in well differentiated carcinoma from various 
institutional series shows a better 10 year survival for papillary cancer, 
ranging between 74% and 93% as compared to follicular cancer, with a 
10 year survival of 43% to 94%. Although many institutions have 
reported their data based on these histologic subcategories, a more 
meaningful system is to categorize patients according to definite risk 
factors more pertinent to generating prognostic information. The risk 
categorization scheme developed at the Lahey clinic, by Cady and group 
carries the acronym AMES (Age, Metastatic disease, Extrathyroidal 
extension, Size). A group from Canada added an assessment of the DNA 
content by flowcytometry to this which carries the acronym DAMES 
with the DNA content, and showed that the highrisk patients with 
aneuploid tumours have a poor long term survival. The initial system 
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developed at the Mayo clinic group in 1987 by Hay and associates carried 
the acronym AGES (Age, Grade of the tumour, Extent of tumour, Size). 
A mathematical formula to develop a PS with different weights on these 
factors was developed. A more recent modification of this system is seen 
in MACIS (Metastasis, Age, tumor extent divided into Completeness of 
the surgery, Invasion and tumor Size). The MACIS scale is a more 
sophisticated post operative system modified from AGES scale. In 
addition some studies have reported that incomplete resection of the 
gland, vascular invasion, male sex, lymph node metastases, certain 
morphologic variants of PTC and tumour multicentricity are significant 
prognostic factors. 
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Prognostic Risk Categorization Schemes 
AMES categorization scheme 
 LOW RISK HIGH RISK 
Age 
 
Metastases 
 
Extent 
 
 
 
Size 
 
Definition 
 
 
 
 
Overall survival (OS) 
 
Disease survival 
(DFS) 
Male <41, female <51 
 
Absent 
 
Intrathyroidal papillary 
or 
follicular with minor 
capsular invasion 
<5 cm 
A: Any low risk age 
group without 
metastases. 
B: High risk age 
without 
metastases and with 
low 
risk extent and size 
98% 
 
95% 
Male >40, female >50 
 
Present 
 
Extrathyroidal 
papillary or 
Follicular with major 
capsular invasion 
> 5 cm 
 
A: Any patient with 
metastases. 
B. High risk age with 
either high risk extent 
or 
size. 
54% 
 
55% 
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DAMES categorization scheme 
LOW RISK Low-risk AMES + 
euploid 
DFS-92% 
INTERMEDIATE 
RISK 
Low-risk AMES + 
aneuploid 
DFS-45% 
HIGH RISK High risk AMES + 
aneuploid 
DFS-0% 
 
AGES categorization scheme 
PS= 0.05 x age in years (age < 40 yrs= 0), 
+ 1 (grade 2) or + 3(grade 3-4), 
+ 1 (if extrathyroidal) or + 3 (if distant metastases), 
+ 0.2 x tumour size (in cms). 
 
PS range= 0- 11.65, median=2.6 
Risk categories: 
0- 3.99 (DFS - 20 yrs - 99%); 
                         4- 4.99 (DFS - 20 yrs - 80%); 
                         5- 5.99 (DFS - 20 yrs - 33%); 
                        > 6 (DFS - 20 yrs - 13%). 
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MACIS categorization system 
PS= 3. I (age< 39 yrs) or 0.08 x age (if age > 40 yrs), 
+0.3 x tumour size (in cms), 
+ 1 (if incompletely resected), 
+ 1 (if locally invasive), 
+3 (if distant metastases are present). 
 
Risk categories: 
0-5.99 (DFS-20 yrs- 99%); 
6-6.99 (DFS-20 yrs- 89%); 
7-7.99 (DFS-20 yrs- 56%); 
>8 (DFS-20 yrs- 24%). 
 
DE GROOT CLASSIFICATION FOR PAPILLARY CARCINOMA 
 There are some other classification systems such as the DeGroot 
classification, SAG risk analysis system and the Mazzaferi staging system 
used in the risk categorization of papillary carcinomas of the thyroid. 
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CLASS EXTENT DISEASE RELATIVE RISK OF 
MORTALITY 
I INTRATHYROIDAL 1 
II CERVICAL 
METASTASIS 
1 
III EXTRATHYROIDAL 
INVASION 
5.8 
IV DISTANT 
METASTASIS 
47 
 
MANAGEMENT OF THYROID MALIGNANCIES 
Management of differentiated carcinomas of the thyroid 
1. Surgery: 
 The key decision in the surgical management of thyroid nodules or 
cancers is whom to operate on and how extensive a resection to perform. 
Extent of thyroidectomy 
 A long standing controversy among endocrine surgeons has existed 
regarding the extent of surgical resection for well differentiated thyroid 
cancer. Technical contributions of surgeons such as Kocher, Lahey, Crile, 
Perzik, Attie, Thompson and others has established thyroidectomy safe 
and effective and it is the primary treatment for patients with well 
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differentiated carcinomas of the thyroid. However, for low risk patients, 
conflicting views by experts persist. For patients in the high-risk 
category, there is much less disagreement regarding the extent of the 
surgery, although there are still some proponents of less than total or near 
total thyroidectomy. 
Acceptable surgical procedures to remove thyroid neoplasm include: 
(i)   Hemithyroidectomy (total removal of one lobe and the isthmus). 
(ii)  Sub-total thyroidectomy (total lobectomy leaving a rim of 2 to 4 
gm of tissue in the upper lateral portion of the contralateral lobe) 
(iii)  Near-total thyroidectomy (total lobectomy and subtotal resection 
on the contralateral side to leave less than 19m of thyroid tissue). 
(Hartley-Dunhill procedure) 
(iv)  Total thyroidectomy. 
 The difference between a total thyroidectomy and a near total 
thyroidectomy usually depends on the particular anatomy of the thyroid 
in any given patient. There may be a small ledge of thyroid tissue, called 
the tubercle of Zuckerkandl, at the ligament of Berry that may limit safe 
resection of the thyroid gland. 
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 Setting apart all the controversies, total thyroidectomy is the 
treatment of choice for virtually all patients with PTC when postoperative 
radioiodine therapy is being considered. This basically includes all 
patients except those with occult PTC < 1 cm). Even in patients with low 
risk PTC, total or near-total thyroidectomy is associated with lower rates 
of recurrence and mortality. When a total thyroidectomy cannot be 
performed without injury to the recurrent laryngeal nerve or parathyroid 
glands, a near total thyroidectomy is performed and the small amount of 
thyroid tissue left behind can subsequently be ablated with radioactive 
iodine. This controversy also exists with follicular carcinomas, with 
conservative surgeons advocating less aggressive procedures for small 
tumours < l cm. However in most centers a total thyroidectomy with 
postoperative radioiodine ablation is performed for all tumours beyond 
stage I. A combination of total or near-total thyroidectomy and I131 
ablation increases the sensitivity of diagnostic I131 total body imaging in 
the search of metastases and allows the destruction of residual 
microscopic disease. The removal of normal thyroid tissue is also a 
prerequisite for postoperative measurements of serum thyroglobulin, a 
tumour marker used to detect recurrent disease. 
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ARGUMENTS FOR AND AGAINST CONSERVATIVE AND 
RADICAL SURGERIES IN WELL-DIFFERENTIATED 
CANCERS OF THYROID 
            ISSUE CONSERVATIVE 
SURGERY 
RADICAL 
SURGERY 
Prognostic risk factors 
 
 
 
Safety of surgery 
 
 
 
 
Postoperative iodine 
 
 
 
 
Anaplastic cancer 
 
 
 
 
 
Thyroglobulin 
Follow-up 
 
Multicentricity and 
Recurrence 
Systems to define risk 
can accurately identify 
patients developing 
recurrence. 
No risks of permanent 
Minimal complications 
with hypocalcemia or 
recurrent  laryngeal 
nerve injury 
If necessary I131 
ablation can be 
accomplished with 
no morbidity. 
 
Local recurrence able 
to be managed: risk of 
anaplastic cancer <1%. 
 
 
 
Not possible. 
 
Tumor multicentricity 
seems to have little 
prognostic significance.
An occasional low risk 
patient develops 
recurrence. 
 
Minimal complications
with experience 
surgeons. 
 
 
Thyroid ablation with 
I131 is complicated 
with pain and 
decreased efficacy 
with thyroid remnant. 
Potential for local 
recurrence with 
possible 
dedifferentitation to a 
more aggressive 
tumour. 
 
 
Possible and an 
accurate 
marker. 
Eliminates the 
contralateral cancers at 
the 
sites of recurrence 
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Role of frozen section 
 There have been few careful reviews of the value of frozen section 
examination in the management of thyroid cancer. Frozen section is 
unnecessary when a FNAC diagnosis is either benign or malignant. In 
case of suspect findings it would be of value and hence it is 
recommended that frozen section be reserved for lesions with persistently 
non-diagnostic results on FNA, for confirmation of lymph node 
metastases and for thyroid nodules diagnosed during surgery and not 
previously sampled.76 Although the sensitivity of frozen section was 
only 62.5%, 58.3%, and 75% in benign, suspect and inadequate FNA 
cases respectively, the technique did permit the identification of some 
unrecognized malignant lesions at the time of surgery and influenced the 
extent of resection. The patients are undoubtedly spared of the second 
surgery to complete a total thyroidectomy when a malignant diagnosis is 
confirmed. Hence intraoperative frozen section for the thyroid nodular 
disease can be of value when FNA results are reported as benign, suspect 
or inadequate, although there are some limitations regarding its 
sensitivity. When FNA is reported as malignant, frozen section is 
unnecessary. 
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TOTAL THYROIDECTOMY – OPERATIVE PROCEDURE 
Positioning of the patient 
 The patient is placed in the supine position with the arms tucked 
close to the side. A rolled towel is placed vertically between the scapula 
and beneath the vertebral column so that the shoulders can fall away from 
the operative field, thus exposing the neck and the upper chest. 
Skin incision, exposure of the thyroid 
 The skin incision is made approximately two finger-breaths above 
the sternal notch. The lateral borders of the incision can approach the 
medial borders of the sternocleidomastiod muscle but can be lengthened 
if the lateral neck is to be investigated. It ordinarily extends laterally to 
the jugular veins; however it might be necessary to extend the incision 
depending upon the size of the thyroid gland and the presence of enlarged 
lymph nodes lateral to the gland. Subplatysmal skin flaps are raised, 
superior flap extending till the thyroid cartilage and the inferior flap till 
the sternal notch. Self-retaining retractors are then placed. The strap 
muscles are separated in the midline for full extent of the operative field. 
The side of the neck on which the thyroid mass is located should be 
explored first. If the thyroid mass is invading the strap muscle or is tightly 
adherent to the muscle the strap muscles can be excised. For adequate 
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exposure, it is necessary to elevate the thyroid lobe and retract it 
medially. As the lobe is elevated the adjoining strap muscles are swept 
away from the gland and retracted laterally. At this point the recurrent 
laryngeal nerve is identified. It is also important to identify the 
parathyroids as one prepares to resect the lobe containing the thyroid 
mass. The lower pair is situated within or immediately adjacent to the 
thyrothymic ligament and the upper pair is located on the posterior 
surface of the midportion of the gland surrounded by a lobule of fat close 
to the point at which the inferior thyroid artery enters the thyroid 
parenchyma 
Resection of the thyroid lobe 
 The thyroid lobe is retracted medially and arteriorly and the lateral 
tissues are swept posterolaterally using a peanut sponge. The middle 
thyroid veins are ligated and divided. The fascia just cephalad to the 
isthmus is divided. The superior thyroid pole is identified by retracting 
the thyroid inferiorly and medially, and then the upper pole is mobilised 
caudally and laterally. The dissection place is kept as close to the thyroid 
as possible and the superior pole vessels are individually identified, 
skeletonized, ligated, and divided low on the thyroid gland, to avoid 
injury to the external branch of the superior laryngeal nerve. The 
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recurrent laryngeal nerve then should be identified within 1 cm of the 
crossing of the inferior thyroid artery and the RLN. The lower pole of the 
thyroid gland should be mobilised by gently sweeping all tissue dorsally. 
The inferior thyroid vessels are dissected, skeletonized, ligated divided as 
close to the surface of the thyroid gland as possible, minimize 
devascularisation of the para thyroids or injury to the RLN. Once the 
Berry ligament is divided, the thyroid can be separated from the 
underlying trachea by sharp dissection. If a lobectomy is to be performed 
the isthmus divided flush with the trachea on the contralateral side and 
suture ligated. The procedure is repeated on the opposite side for a total 
thyroidectomy. During the course of total thyroidectomy, every effort 
should be made to identify the parathyroid glands and if their blood 
supply cannot be preserved they should be resected and placed in iced 
saline. These glands are very hard and are viable for hours in this state. If 
at the completion of the thyroidectomy, it is necessary to remove all four 
glands, one or more of them should be auto grafted into a muscle bed, 
most often in the sternocleidomastoid. After ensuring that there is no 
bleeding in the bed, the strap muscles are then approximated. The 
platysma is closed with interrupted sutures and then subcuticular suturing 
is done. 
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Lymph node dissection 
 The surgical management of lymph node metastases from well 
differentiated thyroid cancer is no longer controversial. Gross cervical 
metastatic disease is treated by modified radical neck dissection, which 
results in excellent local control and minimal morbidity. Even though 
80% of patients with PTC have occult cervical lymph node metastases 
most of these metastases can be ablated with radioiodine treatment 
postoperatively, and some does not appear to grow. Central compartment 
(medial to the carotid sheath) lymph nodes are frequent in word in 
patients with papillary, medullary and Hurthle cell carcinomas, and 
should be removed at the time of thyroidectomy, preserving the recurrent 
laryngeal nerves and parathyroid glands. Central Neck dissection is 
particularly important in patients with medullary and Hurthle cell 
carcinoma because of the high frequency of microscopic tumor spread 
and because these tumors cannot be abalated with I131. An ipsilateral 
modified radical neck dissection is indicated in the presence of palpable 
cervical lymph nodes or prophylactically in patients with medullary 
carcinoma when the thyroid lesion is larger than 1.5 cm. Because 
contralateral lymph node metastases are uncommon (about 10%) a 
contralateral neck dissection is performed only when gross evidence of 
lymph node metastases is found. 
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RADIOIODINE THERAPY 
 The postoperative treatment of patients with well differentiated 
thyroid cancer, particularly relating to radiotherapy, is some what 
controversial. All patients who have undergone a total or near total 
thyroidectomy for papillary or follicular Carcinoma larger than 1 to 1.5 
cm should be considered candidates for radio iodine ablation. I131 
ablation decreases tumor recurrence, development of distant metastases, 
and cancer death. Some studies have failed to detect an enhanced survival 
with the use of radio iodine ablation, particularly in low risk patients as 
defined by AMES criteria The majority of follicular cell derived 
differentiated thyroid carcinomas (75% or more) retain the capacity to 
take up and concentrate iodine, although frequently rather less efficiently 
than normal thyroid tissue. 
Mode of action: 
 Administered orally, iodine isotopes are absorbed rapidly and 
reliably from the upper gastrointestinal tract, circulate in the bloodstream 
and concentrated in the tissues that express a functional sodium iodine 
transporter (NIS). These tissues include normal and cancerous thyroid 
tissue, salivary gland, breast, stomach and the colon. This NIS is also 
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expressed in the kidney, which transports and filters iodine arid 
circulating iodine is excreted rapidly through the urine and stool. 
 The uptake of iodine into both normal and cancerous thyroid tissue 
is dependant on TSH and hence a hypothyroid state has to be created 
when I131 uptake is needed. The treatment of thyroid carcinoma with 
radioiodine depends upon the emission of β-particles emitted by the 
decay of radioiodine. These moderate and high-energy β-particles travel 
only short distances, on an average around 0.5 cm. They result in 
ionization and generation of superoxide radicals, which cause DNA 
damage. As the cancer cells lack efficient mechanisms to repair double 
strand breaks in the DNA the thyroid cancer cells are more susceptible to 
the effects of P radiation. The serum TSH levels, amount of residual 
normal thyroid tissue, degree of differentiation of the PTC and the 
patient’s age all affect the amount of radioactive iodine uptake 
Complications of High dose Therapy with I131 
 The most common side effects from radio iodine therapy include 
sialadenitis, nausea, and temporary bone marrow suppression. Testicular 
function and spermatogenesis are transiently impaired but appear to 
recover with time. There is a dose dependent in relationship between I131 
therapy and the development of leukemia. A higher incidence of bladder 
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carcinoma has been seen in patients who have received high cumulative 
doses of radio iodine. Pulmonary side effects include pneumonitis and 
pulmonary fibrosis. 
External radiation therapy 
 Conventional radiation therapy may be detrimental to the success 
of radioiodine therapy in thyroid adenocarcinoma and should not precede 
therapeutic efforts with radio iodine. External radiation therapy is the 
management of thyroid cancer has been preserved for anaplastic 
carcinoma and lymphoma and differentiated cancer that does not 
concentrate radioiodine. Beneficial results with 35 to 70 Gy have been 
reported in the treatment of local recurrence in some differentiated 
cancers that did not take up radio iodine. In older patients with invasive 
papillary cancer and positive lymph nodes, 50-60 Gy external radiation 
significantly reduced the 10 year recurrence rate. 
Postoperative follow up 
 The follow up of patients with differentiated thyroid carcinoma 
include physical examination, monitoring of thyroglobulin levels, I131 
whole body scanning, radiographic imaging and functional nuclear 
imaging. 
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1. I131 whole body scan:  
 Whole body scan is most sensitive when there is minimal remnant 
thyroid tissue. Significant amounts of thyroid tissue may result in failure 
to detect metastatic disease. Tumours that are poorly differentiated, 
tumours in older patients and particularly Hurthle cell carcinoma may not 
concentrate iodine; this limits the usefulness of whole body thyroid scan. 
Patients stop using thyroid hormone 3 to 6 weeks before scanning to 
induce hypothyroidism. They are then administered tracer doses of I131, 
usually 1 to 5 mCi. There occurs a stunning effect of doses above 
approximately 3 mCi, which results in reduced intake of subsequent 
doses of I131. Consequently for whole body scanning, doses of 3 mCi are 
nowadays used. These scans are repeated at regular intervals for duration 
depending on the risk of the patient. 
2. Serum thyroglobulin:  
 Thyroglobulin is a large glycoprotein that is synthesized by the 
follicular cells and secreted and stored in the colloid lumen, where it is 
iodinated. Later it is reabsorbed by the follicular cells, hydrolyzed and 
released as thyroid hormone. It is detectable in the serum in 75% to 90% 
of healthy adults (normal levels- 0 to 30 ng/ml). After a total 
thyroidectomy, serum thyroglobulin is expected to be low or 
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undetectable. Detectable TSH indicates either residual thyroid tissue or 
recurrent differentiated thyroid cancer. The magnitude of thyroglobulin 
levels may be related to the tumour mass, degree of differentiation and 
the location of the metastases. A thyroglobulin level of 2 ng/ml or more 
in euthyroid patients and above 10 ng/ml in hypothyroid patients usually 
indicates recurrent differentiated thyroid carcinoma. 
3. Ultrasound:  
 Ultrasound (USG) is commonly used in the postoperative 
management of thyroid carcinoma to detect local or regional disease 
recurrence. Advantages include the ability to detect non-palpable 
recurrent disease and the ability to perform a simultaneous USG-guided 
FNA for diagnosis. USG does not use ionizing radiation, does not require 
thyroxin withdrawal and it may detect recurrent disease in approximately 
10% of cases in whom serum thyroglobulin in false negative. It may be 
useful in patients in whom thyroglobulin measurement is not reliable. 
4. Magnetic resonance imaging (MRI): 
 MRI is sometimes used in the follow up of patients with 
differentiated thyroid carcinoma to detect the local or regional recurrence 
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when serum thyroglobulin is elevated, and other testing like I131 whole 
body scan fail to localize disease recurrence. 
5. Positron emission tomography (PET): 
 It is now clear that poorly differentiated carcinomas are much more 
likely to concentrate F18-Fluorodeoxyglucose than I131. Hence the PET 
is found to be 50% to 85% sensitive in the localization of thyroid cancer 
that does not concentrate I131 but whose presence is known secondary to 
elevated levels of thyroglobulin. Identification of these metastatic sites by 
FDG scanning may lead to significant alteration in the management of 
these patients. 
Postoperative thyrotropin suppression 
             Thyroid stimulating hormone (TSH) acts as a potential growth 
factor on any thyroid tissue remaining after surgical or radioactive iodine 
treatment. Therefore suppression of TSH levels should be achieved with 
comparatively high doses of oral T4 continued for life, with attention to 
the potential thyrotoxic effects such as atrial fibrillation and cardiac 
compensation. Even though TSH controls the thyroid gland function, its 
role in the tumourigenesis is unclear. But most investigators have 
reported an improved survival and lower recurrence rate in patients with 
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TSH suppressive therapy. The standard dose prescribed after a total 
thyroidectomy is 0.1 to 0.2 mg daily. Failure of TSH suppression to a 
level <0.1 mU/.L indicate an inadequate dose of thyroxine. Suppressive 
dose of thyroxine is probably not of value in follicular carcinoma and is 
unlikely to be of benefit in low-risk patients treated with lobectomy. 
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METHODOLOGY 
Source of data 
 Cases admitted as inpatients in various surgical wards in Madras 
Medical College and RGGGH with signs and symptoms of carcinoma 
thyroid, who are clinically evaluated and confirmed by FNAC were 
chosen for study. 
Methods of collection of data: 
•  A Performa for study of all consecutive patients of carcinoma 
thyroid was used. The presentation, clinical findings, investigations 
and line of management were documented. 
•  Between JULY 2012 – DECEMBER 2012 , 30 cases of carcinoma 
thyroid were selected on the basis of simple random sampling 
technique and clinically evaluated. 
•  The patients confirmed by FNAC were subjected to surgery . 
•  The patients were followed up a month after surgery and 
underwent thorough clinical examination, investigative procedures 
like chest X-ray, thyroglobulin assay, radioiodine scan for 
locoregional recurrence or distant metastasis. 
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Inclusion criteria 
 The patients presenting with symptoms and signs of carcinoma 
thyroid and diagnosed by FNAC in various surgical wards in MMC & 
RGGGH were selected. 
Exclusion criteria 
1.  Patients with benign thyroid disorders 
2.  Patient who refused any mode of treatment. 
3.  Patients less than 12 years of age. 
4.  Patients who have previously been treated surgically for any 
thyroid ailments. 
Mode of selection 
 All patients admitted to Madras Medical College & RGGGH 
during the course of study, who have positively diagnosed as having 
thyroid malignancies by investigations have been selected. The study 
required certain investigations to be conducted on the patient viz. routine 
blood investigations, thyroid function tests when needed, x-ray chest and 
neck, fine needle aspiration and cytological diagnosis. Indirect 
laryngoscopy was done in all patients to determine the status of the vocal 
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cords specifically their movements. The study also required certain 
intervention to be conducted on patients like biopsy for diagnosis as in 
case of lymphoma or anaplastic carcinomas. All the investigations and 
interventions were done only after the proper consent from the patients. 
Statistical tests 
 The statistical tests used in this study are the test of proportion and 
percentage. 
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Fig 13 ANAPLASTIC CA THYROID                                                   
 
Fig 14 FOLLICULAR CA THYROID       
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RESULTS 
 The study consists 30 cases of proven thyroid carcinoma who were 
admitted in various surgical wards during the period July 2012 to 
December 2012 in  MMC & RGGGH, CHENNAI. 
INCIDENCE OF THYROID CARCINOMA 
 In the study period; 1965 patients were admitted in MMC & 
RGGGH with different types of malignant diseases (Medical Records 
Division, MMC & RGGGH, CHENNAI) of which thyroid cancer 
constitutes 1.53% (30 out of 1965). 
AGE INCIDENCE 
Table 1: Age incidence in thyroid malignancies 
Age (in years) No of cases Percentage 
0-9 0 0 
10-19 1 3 
20-29 6 20 
30-39 11 36 
40-49 6 20 
50-59 2 7 
60-69 2 7 
70-79 2 7 
80-89 0 0 
90-99 0 0 
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Figure 15 : Age incidence 
 
Table 2: Age incidence in different thyroid malignancies 
Age(yrs) Papillary Follicular Medullary Anaplastic Lymphoma
0-9 0 0 0 0 0 
10-19 1 0 0 0 0 
20-29 5 1 0 0 0 
30-39 8 3 0 0 0 
40-49 4 2 0 0 0 
50-59 1 1 0 0 1 
60-69 1 0 0 1 0 
70-79 1 0 0 0 1 
80-89 0 0 0 0 0 
90-99 0 0 0 0 0 
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               Fig 16 : Age Incidence In Thyroid Malignancies 
 In this series, it was found that thyroid carcinoma is commonly 
seen in the age group of 30-39 and the common type of malignancy seen 
is the papillary thyroid carcinoma. The most commonest histological type 
(i.e. papillary carcinoma) is also common in fourth decade. 
Sex incidence: 
1. Number of female patients – 25 
2. Number of male patients – 5 
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Table 3: Sex incidence in relation to type of malignancy 
TYPE FEMALE MALE PERCENTAGE 
PAPILLARY 17 4 21(70%) 
FOLLICULAR 6 1 7 (23%) 
ANAPLASTIC 1 0 1(3%) 
MEDULLARY 0 0 0 
LYMPHOMA 1 0 1(3%) 
TOTAL 25 5 30 
 
Male to female ratio was 5:1 in the study. 
FIG 17  Sex incidence in thyroid malignancies 
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TABLE 4: Clinical features in thyroid malignancies 
SYMPTOMS NO OF CASES PERCENTAGE 
THYROID SWELLING 28 93 
LYMPH NODE MASS 2 7 
HOARSENESS 3 10 
DYSPNEA 2 6 
DYSPHAGIA 2 6 
HYPERTHYROIDISM 0 0 
DIARRHOEA 0 0 
DISTANT 
METASTASIS 
1 3 
 
FIGURE 18 : Clinical features of thyroid malignancy 
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 In study, patients predominantly presented with swelling of the 
thyroid (93%), followed by hoarseness of voice (10%). Most common 
pressure effect is hoarseness of voice, which was present in 10% of the 
patients. Only 6% of patients in study had symptoms of dyspnoea and 
dysphagia, and 3% had presented with distant metastases. 
Duration of Thyroid Swelling 
 Of the 30 patients who presented with thyroid swelling most of the 
patients noticed the swelling in a period less than 3 months (23%). Sixty 
percent of the patients presented with swelling of less than one year 
duration. 
TABLE 5: Duration of thyroid swelling in thyroid 
malignancies
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FIGURE 19 : Duration of thyroid swelling in thyroid malignancies 
 
 
Indirect Laryngoscopy 
 Indirect laryngoscopy done in the patients under study revealed 
vocal cord palsy in four of the patients. Three had papillary carcinomas 
and all of them underwent near-total thyroidectomy and the other was 
follicular variant of papillary carcinoma thyroid. 
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Radiological findings 
Radiograph of the neck is made in the antero-posterior and the lateral 
views. The radiograph in 6 of the patients showed tracheal deviation and 
it showed calcifications in 3 of the patients. The rest of the patients 
showed normal radiograph of the neck. 
TABLE 6  : Radiological findings 
 
 
FIGURE 20: Radiological findings 
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Staging 
 The patients were staged based on the AJCC 2002 staging system 
and the results are as follows 
TABLE 7  Staging Of Thyroid Malignancies 
 
FIG 21  Staging Of Thyroid Malignancies 
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 Most of cases after investigations and pathological reporting were 
found to be Stage I (53%) as most of patients in the study had 
differentiated thyroid carcinomas and most of them were below 45 years 
of age. Stage IVA was the next commonly seen stage of the disease and 
the patients constituted 20% of the patients in the study. 
SURGICAL TREATMENT 
TABLE 8: Surgery for the primary disease 
 
Fig  22  Surgery For Primary Disease 
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 The most commonly performed surgery in the study was total 
thyroidectomy. Twenty 20 patients (67%) underwent total thyroidectomy. 
Most of these patients were proven papillary carcinoma on cytology or 
suspicious of malignancy during surgical procedure. The patients 3 in 
number (10%), whose cytology turned out to be follicular neoplasm, and 
with a solitary nodule, initially underwent hemithyroidectomy, and later a 
completion thyroidectomy after the histopathological report. Five of the 
patients in the study  had infiltration of the recurrent laryngeal nerve by 
the tumour and these patients underwent a near-total thyroidectomy 
leaving minimal thyroid tissue adjoining the recurrent laryngeal nerve. 
Two of the patients with follicular neoplasm underwent initially a 
hemithyroidectomy and their histological report was follicular carcinoma. 
However in view of their low-risk status and the associated poor medical 
condition the patient was advised follow-up. 
Surgery for Nodal Secondaries 
 Three of the patients who presented with cervical 
lymphadenopathy underwent functional neck dissection for level II, III 
and IV group of cervical lymph nodes. 
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PATHOLOGY 
FNAC Results 
 Both FNAC and biopsy were done in 475 cases during the study. 
The results are as follow 
TABLE 9  FNAC  RESULTS 
 
FIG 23  FNAC RESULTS 
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Table 10: Statistical methods 
 
 Reporting of follicular neoplasm is taken as inconclusive and 
excluded from the statistics. Total of 475 cases underwent both FNAC 
and biopsy. Out of this, 19 FNA were reported as inadequate material. In 
another 54 cases the FNAC report was follicular neoplasm. All of them 
turned out benign, either follicular adenoma or other benign lesion. 
Histopathological Results 
 Four of the patients with papillary carcinoma had the histology of 
follicular cell variant type. The predominant variety is papillary 
carcinoma (61%) and the next common type in the study is follicular 
carcinoma. None of the other variants of papillary and follicular 
carcinomas were found in the histopathological study. 
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TABLE 11: Histopathological types of thyroid carcinoma 
 
FIG 24   Histopathological types of thyroid malignancies 
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Lymph Node Involvement 
 Two patients with papillary carcinoma thyroid had lateral cervical 
group lymphadenopathy (lever III and IV). 
Risk Categorization 
 Among the 30 patients III the study 28 patients had well 
differentiated carcinomas of follicular cell origin. These patients were 
categorized into low and high risk groups based on the AMES 
categorization scheme. 
TABLE 12  AMES categorization scheme for well-differentiate 
carcinomas 
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FIG  25  AMES categorization scheme for well-differentiated 
carcinomas 
 
 
 
            When all patients with well-differentiated thyroid carcinomas 
were considered 75% of the patients were of the “low-risk” category and 
25% were of the “high-risk” category. If patients with papillary thyroid 
carcinomas are alone considered 71% are of “low-risk” and 29% are of 
“high-risk” categories. 86% and 14% of follicular carcinoma patients 
were of “low” and “high” risk categories. 
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Complications of Surgery 
           All the patients were observed in the immediate post-operative 
period. The patients underwent indirect laryngoscopy in case they 
complain of hoarseness of voice, and the serum calcium was estimated if 
the Trousseau’s sign (inducing carpopedal spasm by occlusion of the arm 
with a blood pressure cuff for 3 minutes) was positive. 
TABLE 13  Complications of surgery 
 
FIG  26  Complications of surgery 
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 All symptomatic hypocalcemic patients were treated with 10 ml of 
10% calcium gluconate slow i.v. Less severe cases were treated with oral 
calcium supplements along with vitamin D. All the patients recovered in 
the immediate postoperative period. One patient suffered recurrent 
laryngeal nerve palsy postoperatively. None of the patients had wound 
infection. Among the patients who came for regular follow up none of the 
patients developed hypocalcemia on a long term. 
POST OPERATIVE ADVICE 
 One patient who had anaplastic carcinoma was advised to undergo 
external beam radiotherapy. One patient who had lymphoma (NHL) was 
advised to undergo combined chemotherapy and external radiotherapy. 
All patients were started on the thyroxine therapy postoperatively. 
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DISCUSSION 
INCIDENCE 
 In the TATA MEMORIAL HOSPITAL, MUMBAI, thyroid 
malignancies constituted 1.5% of all malignancies admitted in the year 
1999. In the present Study thyroid malignancies accounted for 1.53% of 
all the malignancies admitted in MMC & RGGGH. In study conducted at 
ADYAR CANCER AND RESEARCH INSTITUTE, CHENNAI(2006 – 
2008), thyroid malignancies formed about 2.16 %  of all cases of 
malignancies. 
TABLE 14: Incidence of thyroid malignancies – comparison 
THYROID 
MALIGNANCIES 
TATA 
MEMORIAL 
HOSPITAL 
PRESENT 
STUDY 
ADYAR 
CANCER 
INSTITUTE 
PERCENTAGE 
OF TOTAL 
MALIGNANCIES 
1.5 % 1.53% 2.16% 
 
AGE INCIDENCE 
 Dave RI et al. (1983) and Bansali et al. (1979) have studied the age 
incidence of thyroid carcinoma and have reported that the commonest age 
group affected is the 5th and the 6th decade respectively. In the present 
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study the 4th decade is commonly affected. This may be due to the 
increased awareness among the people in recent days. 
SEX INCIDENCE 
 The study conducted in England and Wales in 1993 to know the 
sex ratio of hormone dependant cancers by Dos Santos Silva and 
Swerdlow showed that thyroid cancer is predominantly seen in women in 
a ratio of 3:1. In the present study the sex ratio of thyroid malignancies is 
found to be 5:1. 
CLINICAL FEATURES 
 The predominant symptom in the present study was thyroid mass 
which was also the predominant symptom in the study conducted by 
Simon Holzer et al. in 1996 in Germany and published in 2000; which 
was also the predominant symptom in Kannan RR study of 670 Cases of 
carcinoma thyroid from 1956 to 1996 in cancer institute, Madras. 
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TABLE 15: Clinical features of thyroid malignancies – Comparison 
 
STAGE OF THYROID CARCINOMA 
 In a study conducted by Simon et al. in 2000 the differentiated 
thyroid carcinomas were staged and their percentages were calculated. 
The table shows that percentage of Stage I and Stage II were almost 
similar in case of papillary carcinoma in two studies. But the incidence of 
stage IV disease was more in present study. In case of follicular 
carcinoma the present study showed predominant stage I disease which 
formed 57% of follicular carcinoma. In the present study, one patient of 
follicular carcinoma presented with stage IV. This difference may not be 
significant as only 7 cases of follicular carcinoma were reported. 
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FIG 27  Stages of thyroid carcinomas in different studies 
 
 
 
 
 
 
 
 
 
 
 
PATHOLOGICAL DISTRIBUTION 
 In the present study the papillary carcinoma was the most common 
type of thyroid malignancy seen in the hospital accounting for about 70 of 
the cases. In the study conducted by Simon et al., papillary thyroid 
carcinoma formed about 66.4% of the study. The proportions of deferent 
types of thyroid malignancies in the present study are similar to dose in 
the study conducted by Simon et al. The reason for the increased 
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incidence of anaplastic carcinoma could be the long term negligence of 
the thyroid swelling, which would have gone for dedifferentiation. 
FIG  28  Various types of thyroid malignancies – Comparison 
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TABLE 16   Correlation of FNAC with  
Histopathology – Comparison 
 
FIG 29  Correlation of FNAC with Histopathology – Comparison 
 
        
 
 
 
 
 
 
 
 
 
  102
 The specificity in the present study is 98.6% which is comparable 
to the specificity in the studies conducted by Jan F Silver man et al. and 
Harsoulis P et al. Sensitivity of the present study is 70% which is lower 
than the other two studies. The low sensitivity in the present study could 
be due to sampling error. The positive and negative predictive value of 
the present study are similar to the results in the other two studies. A 
study at Ankara Oncology Education and Research Hospital, Ankara, 
Turkey, where 650 patients underwent thyroid surgeries and their 
cytological and 
FNAC reports were correlated. 
• Sensitivity - 90% 
• Specificity - 79% 
• False negative - 2% 
 
Surgery for Thyroid Carcinoma 
 Total thyroidectomy remained as the most commonly done surgery 
either primarily or as a completion procedure in the present study. 
Gulliamondegui et al. (1983) reported that total thyroidectomy was the 
most commonly performed surgery for thyroid carcinoma. 
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Lymph Node Involvement 
 In the study done by Simon et al.106 cervical lymph node 
involvement was found in 6.6% of papillary carcinomas and 3.3% of 
follicular carcinomas. In the present study none of the patients with 
follicular carcinomas had cervical lymph nodal involvement, and all the 
patients who had such involvement had papillary carcinomas 
TABLE 17  Incidence of lymph node metastases in  
various types of thyroid carcinoma 
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CONCLUSION 
1.  The incidence of thyroid malignancy in the present study is 1.53% 
comparable to incidence in other parts of India. 
2.  The incidence of thyroid cancer is higher in female when compared 
to those reported in the literature. 
3.  The most common mode of clinical presentation was thyroid 
swelling which was higher than those in comparative study. 
4.  FNAC is an inexpensive accurate and practical investigation for 
evaluation of thyroid carcinomas. 
5.  The accuracy of FNAC to diagnosing thyroid cancer was similar to 
that reported in literature. The low sensitivity may be due to 
sampling error. 
6.  The proportion of different histopathological types of thyroid 
cancer were similar to those reported in literature. 
7.  The most common complication was transient hypoparathyroidism 
which resolve with calcium supplementation. 
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SUMMARY 
 A total number of 30 patients with thyroid cancer were evaluated in 
the study period from JULY 2012 to DECEMBER 2012 IN MMC & 
RGGGH. A brief introduction and historical review of thyroid cancer has 
been presented with a detailed review on surgical anatomy, pathology, 
clinical evaluation, investigations including FNAC and management. 
The findings of the study are as follows: 
1.  Thyroid malignancies constitute 1.53% to 2% of all malignancies. 
2.  The occurrence of thyroid cancer was maximum in the 4th decade 
of life. 
3.  Female patients outnumbered males with a ratio of  5: 1. 
4.  Commonest symptom of thyroid malignancy was a painless 
swelling in the front of the neck (93% of the patients). 
5.  Most common clinical presentation with thyroid swelling was 
MNG. 
6.  Duration of symptoms varied greatly; with 60% of the patients 
presenting with a duration of  less than 1 year. 
7.  A large number of patients belonged to AJCC (2002) Stage I 
disease (53%). 
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8.  Most common histopathological type was papillary carcinoma 
thyroid (70%); followed by follicular carcinoma thyroid (23%). 
9.  Most of the patients (73%) of well differentiated types of thyroid 
carcinoma belonged to the low risk category according to the 
AMES categorization scheme. 
10.  Most common surgery performed was total thyroidectomy in 
70% of cases with minimal postoperative complications. 
11.  Overall diagnostic accuracy of FNAC is 97% in this study. 
PROFORMA 
 
Unit: IPNo.: S1. No.: 
 
Name: Age: Sex: 
 
Religion: Occupation: Address 
 
DOA: DOO: DOD: 
 
I. Chief Complaints 
 
II. History of Present Illness 
 
1.  Swelling in the Neck: 
 Onset 
 Duration: 
 Rate of growth 
 Associated with pain 
 
2.  Pain: 
 Duration 
 Character 
 Radiation 
 
3.  Pressure effect: 
 Dyspnoea 
 Dysphagia 
 Hoarseness of voice 
 
4.  Symptoms of Thyrotoxicosis 
 Loss of weight 
 Preference of cold 
 Intolerance to Heat 
 Excessive sweating 
 Insomnia 
 Tremor of hands 
 Palpitation 
 Chest Pain 
 Diplopia 
5.  Symptoms of Hypothyroidism 
 Increase in weight 
 Intolerance to cold weather 
 Facial swelling 
 Constipation 
 Somnolence 
 
III. Past History 
 
   Drug Intake: 
 
IV. Personal History 
 
   Diet: 
 
V. Menstrual History 
 
VI. Family History 
 
 
VII. General Examination 
 
1.  Built & Nourishment 
2.  Facies 
3.  Mental state & intelligence 
4.  Pulse 
5.  Sleeping pulse rate 
6.  Temperature 
7.  Respiratory rate 
8.  Blood pressure 
9.  Eye signs 
 Lid retraction 
 Exophthalmos 
 Ophthalmoplegia 
 Chemosis 
 
10.  Tremor 
 
11.  Skin 
 
VIII.  Local Examination 
 Inspection 
 
 Swelling in anterior aspect of Neck 
 Size 
 Surface 
 Movement with deglutition 
 Movement with tongue protrusion 
 Edge 
 Lower Borders 
 Other Swellings 
 Dilatation of veins 
 Congestion of face on raising the hand 
 
Palpation: 
 
 Swelling 
 Size 
 Shape 
 Extent 
 Surface 
 Edge 
 Consistency 
 Plane 
 Mobility 
 Kocher’s test 
 Thrill 
 Bruit 
 Cervical Lymph nodes: 
 Carotid pulsation - Right 
 - Left 
 
IX. Examination of other systems 
 
 Cardiovascular system 
 Respiratory system 
 Nervous system 
 Abdomen 
 
X. Investigation 
 
1.  Haematological Hb 
 TC 
 DC 
 ESR 
2.  Urine Examination Albumin 
 Sugar 
 Micro 
 
3.  Blood sugar 
4.  Urea 
5.  Serum Creatinine 
6.  Thyroid function test T3 T4 TSH 
7.  Radiograph of Neck AP and Lat 
8.  Radiograph of chest PA 
9.  Ultrasonography of the neck 
10.  FNAC 
 
XI. Premedication and anaesthesia 
 
XII. Operative details 
 
XIII. Post operative management 
 
Antibiotics 
IV fluids 
 
Analgesics 
Eltroxin 
Blood transfusion 
Other drugs 
Oral fluids 
Removal of drain 
Features of Hypoparathyroidism 
 
XIV. Histopathological Report 
 
XV. Complications 
 
XVI. Treatment of Complication 
 
XVII. Condition at time of discharge 
 
XVIII. Follow up 
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1. Bhagya  41 F 109874 + 5m - - - - - - - SN EU NG N N I LR TT 
2. Prabha  21 F 98765 + 6m - - - - - - - SN EU PC N N I LR TT 
3. Muniamma 37 F 99874 + 2y - - - - - - - MN EU PC N N I LR TT 
4. Radha 51 F 89743 + 6m - - - - - - - MN EU PC N N II HR TT 
5. Krishnan 46 M 88975 + 6y - - + - - - - SN EU FN N TD I LR HT+CT
6. Kamala 23 F 78654 + 3m - - - - - - - SN EU NG V-R CA I LR HT 
7. Lakshma 64 F 109777 + 1m -- - - RII&
IV 
- - - SN EU NG N N I LR HT 
8. Nagamma 34 F 78954 + 1y + - - - - - - MN EU PC N N IVA LR NTT+
FND 
9. Munusamy 48 M 98765 + - - - - - - - - - EU PC N N I HR TT 
10. Kalaiselvi 23 F 97865 + 2y - - - - - - + MN EU NG N TD II HR TT 
11. Pappamal 62 F 93765 _ 2m - - - - - - - MN EU NG N N IV A LR NTT+
FND 
12. Divya 18 F 87654 + 6m - - - - - - - - EU FC N N III LR TT 
13. Sridevi 32 F 78694 + 7m - - - - - - - SN EU PC V-R TD I LR TT 
14. Rajappan 65 M 90387 _ 8m + - - - - - - MN EU PC N N I HR TT 
15. Gayathri 49 F 109876 + 5y - - - - - - - SN EU PC N CA II LR TT 
16. Ramani 56 F 76589 + 3y - + + - - - - MN EU PC N N I LR TT 
17. Amulu 34 F 71234 + 6m - - - LI&
III 
- - - SN EU FN N N I LR NTT 
18. Veni 29 F 87123 + 8m - - - - - - - MN EU FN V-L N I HR NTT 
19. Ramayee 56 F 89444 + 7m - - - -- - - - MN EU PC V-R TD I LR TT 
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20. Geetha 31 F 111908 + 1y - - - - - - - MN EU NG N CA II LR TT 
21. Shubha 32 F 119834 + 7m - - - - - - - SN EU NG N N IV C HR NTT 
22. Shoba 34 F 56784 + 2y - - - - - - - SN EU FN N N I LR L-
HT+CT 
23. Mahesh 36 M 87692 + 8y - - -- - - - - SN EU PC N N II HR TT 
24. Raagavi 70 F 95810 + 8y - + - - - - - MN EU PC N N I HR TT 
25. Naga 34 M 109111 + 10m - - - - - - - MN EU PC N TD I LR TT 
26. Mangalam 44 F 76578 + 15m - - - - - - - MN EU FN N N III LR TT 
27. Mariya 33 F 83245 + 6y - - + - - - - MN EU NG N N I LR TT 
28. Parimala 56 F 98640 + 2y - - - -- - - - SN EU PC N N IV LR TT 
29. Chitra 34 F 81287 + 1y - - - - - - - MN EU FN N N I HR HT+C
T 
30. Bhuvaneshwari 44 F 101111 + 4m - - - - - - - MN EU PC N CA I LR TT+L
+FND 
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